Current issues in drug reimbursement

Clinical Pharmacology: Current Topics and Case Studies

Volumn , Issue , 2006, Pages 33-50

  Bucsics, Anna ^a  

^a Main Association of Austrian Social Security Institutions   (Austria)

Author keywords

Health technology assessment; Medicines Evaluation Committee; Reimbursement; Relative effectiveness; Transparency Directive

Indexed keywords

EID: 84880290013     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0144-5-4     Document Type: Chapter

References (39)

1. Bismarck versus Beveridge: Social Insurance Systems in Europe CESifo DICE Report 2008 [cited 1 March 2010. 69-71]. Available from: http://www.cesifo-group. de/pls/guestci/results.run-query? v-it-folder-list=2888&v-page-title=CESifo%20DICE%20Report%204/2008%20&v-num-files=25&v-display-resdts=S&v-order-by=autor
2. van der Zee J, Kroneman M (2007) Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Ser Res 7(1):94
3. Frencher SK Jr, Glied S (2006) The Medicare Prescription Drug Improvement and Modernization Act: prescription drugs and academic medicine. Acad Med 81(9):812-816
4. Vogler S, et al. (2008) PPRI Report, [cited 6 March 2010], Available from: http://ppri.oebig.at/index.aspx?Navigation=r |2|0
5. PPRI Pharma Profiles, [cited 6 March 2010], Available from: http://ppri.oebig.at/index. aspx?Navigation=r|2|1
6. Steinbrook R (2006) The Price of Sight - Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. N Engl J Med 355(14):1409-1412
7. CMS LCD for Intravitreal bevacizumab (Avastin®). [cited 15 Jan. 2010], Available from: http://www.cms.hhs.gov/mcd/viewlcd.asp?lcd-id=29961&lcd-version=5&basket=lcd%3A29961%3A5% 3AIntravitreal+Bevacizumab+%28Avastin%C2%AE%29%3AMAC+-+-Part+B%3AFirst+Coast +Service+Options| | +Inc.+%2809302%29%3A op
8. Raftery J, et al. (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91(9):1244-1246
9. National Institute for Health and Clinical Excellence, [cited 1 March 2010], Available from: http://www.nice.org.uk
10. IQWiG Website, [cited 6 March 2010], Available from: http://www.iqwig.de/institute-for-qualityand-efficiency-in-health.2.en.html
11. Haute Autorite de sante [cited 1 March 2010], Available from: http://www.has-sante.fr/portail/jcms/c-5443/english?cid=c-5443
12. Canadian Agency for Drugs and Technologies in Health [cited 1 March 2010], Available from: http://www.cadth.ca/index.php/en/home
13. Pharmaceutical Benefits Advisory Committee (PBAC) [cited 1 March 2010], Available from: http://www.health.gov. au/internet/main/publishing.nsf/content/health-pbs-general-listingcommittee3.htm
14. Eichler HG, Bloechl-Daum B, et al. (2010) Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 9:277-291
15. Legal Basis for the Austrian Reimbursement List [cited 1 March 2010], Available from: http://www.sozialversicherung.at/portal27/portal/esvportal/channel-content/cmsWindow?p-tabid=5 &p-menuid=64740&action=2
16. College voor zorgverzekeringen (CVZ) [cited 1 March 2010], Available from: http://www.cvz.nl
17. Garattini S, Bertele V (2008) Do we learn the right things from clinical trials? Eur J Clin Pharmacol 64(2):115-125
18. ESIP website [cited 6 March 2010], Available from: www.esip.org
19. President Barroso unveils his new team (2009) [cited 6 March 2010], Available from: http://europa.eu/rapid/pressReleasesAction. do?reference=IP/09/1837&format=HTML&aged-0 &language=EN&guiLanguage=en
20. The Department of Health and Human Services [cited 6 March 2010], Available from: http://www.hhs.gov/about
21. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, In DIRECTIVE 89/105/EEC. 1989, THE COUNCIL OF THE EUROPEAN COMMUNITIES: OJ No L 40 of 11. 2. 1989
22. DG III-E3, P. U. Transparency Committee (1999) (Directive 89/105/EEC), 30th March 1999, Summary Report, [cited 6 March 2010], Available from: ec.europa.eu/enterprise/sectors/pharmaceuticals/files/pharmacos/docs/doc99/tc89105-en.pdf
23. European Commission High Level Group on innovation and provision of medicines recommendations for action (2002) [cited 6 March 2010]; Available from: ec.europa.eu/enterprise/sectors/pharmaceuticals/files/phabiocom/docs/glO-medicines-en.pdf
24. The Pharmaceutical Forum (2008) [cited 6 March 2010], Available from: http://ec.europa.eu/pharmaforum
25. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 Dec. 1999 on orphan medicinal products
26. Haynes B (1999) Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving. BMJ 319(7211):652-653
27. Services, U. D.o.h.a. H. Federal Coordinating Council for Comparative Effectiveness Research Report to the President and the Congress (2009) [cited 6 March 2010], Available from: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf
28. Core principles on relative effectiveness (2008) [cited 6 March 2010], Available from: ec.europa.eu/pharmaforum/docs/rea-principles-en.pdf
29. Data availability to conduct on relative effectiveness assessments (2008) [cited 6 March 2010], Available from: ec.europa.eu/pharmaforum/docs/rea-data-en.pdf
30. Development of networking and collaboration (2008) [cited 6 March 2010], Available from: http://ec.europa.eu/pharmaforum/effectiveness-en.htm
31. European network for Health Technology Assessment - EUnetHTA [cited 6 March 2010], Available from: www.eunethta.net
32. European Medicines Agency and EUnetHTA Joint Action start collaboration on European Public Assessment Report (EPAR) contribution to relative effectiveness assessments (2010) [cited 6 March 2010], Available from: http://www.eunethta.net/Public/Communication/Press-Releases/European-Medicines-Agency-and-EUnetHTA-Joint-Action-start-collaboration-on-European-Public-Assessment-Report-EPAR-contribution-to-relative-effectiveness-assessments
33. Overview of the American Recovery and Reinvestment Act of 2009 (Recovery Act) (2010) [cited 6 March 2010], Available from: http://www.ahrq.gov/fund/cefarra.htm
34. Steinbrook R (2009) Health Care and the American Recovery and Reinvestment Act. N Engl J Med 360(11):1057-1060
35. The Cochrane Collaboration [cited 6 March 2010], Available from: http://www.cochrane.org
36. Ray WA, Stein CM (2006) Reform of Drug Regulation - Beyond an Independent Drug-Safety Board. N Engl J Med 354(2):194-201
37. NIH-Private Sector Partnership in the Development of Taxol. [cited 6 March 2010], Available from: http://www.gao.gov/cgi-bin/getrpt?GAO-03-829
38. Kaplan W, Laing R, and Priority Medicines for Europe and the World (2004) [cited 6 March 2010], Available from: whqlibdoc.who.int/HQ/2004/WHO-EDM-PAR-20047.pdf
39. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981-2997